title: Inhibition of spontaneous pulmonary metastases of Lewis lung carcinoma by oral treatment with Respivax and Broncho-Vaxom.
abstract: The antimetastatic activity of orally administered polybacterial vaccines, Broncho-Vaxom (BV) and Respivax (RV) was examined in C57BL/6 mice, bearing implants of Lewis lung carcinoma (3LL) in the footpad. The oral administration of BV or RV for 10 consecutive days before or after surgery caused significant reduction of the number and volume of lung metastases. In addition, the therapeutic potential of BV and RV was examined in combination with chemotherapy to determine if there is additive activity. In animals bearing pulmonary micrometastases, treatment with a combination of cyclophosphamide at 50-150 mg/kg with BV or RV was found to be more effective than each of these treatments alone. In immune function studies it was established that the oral administration of BV and RV induced an increase in the number of cells, recovered by broncho-alveolar lavage, and alveolar macrophages were dominant in these cell populations. Furthermore, oral treatment of mice with these vaccines rendered their alveolar macrophages tumoricidal for syngeneic metastatic 3LL cells in vitro. These results show that pulmonary macrophages induced by oral administration of BV and RV played a key role in the inhibition of metastasis in 3LL-bearing mice.
authors.affiliation: Medical Academy, Department of Experimental Cancer Therapy, Sofia, Bulgaria.
authors.forename: K T
authors.initials: KT
authors.lastname: Kassabov
authors.forename: J N
authors.initials: JN
authors.lastname: Stoychkov
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000284:Administration, Oral; D000818:Animals; D001419:Bacteria; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002457:Cell Extracts; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D007167:Immunotherapy; D008168:Lung / Q000166:cytology / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy; D008262:Macrophage Activation / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D011650:Pulmonary Alveoli / Q000166:cytology / Q000276:immunology; D000095983:Bacterial Lysates
chemical_list: D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D002457:Cell Extracts; D003520:Cyclophosphamide; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates; C060965:respivax